Evaluation of a method to correct the contractility index LVdP/dtmax for changes in heart rate

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 2, 2012, Pages 98-105

  Markert, Michael ^a   Trautmann, Thomas ^a   Groß, Marcus ^b   Ege, Anja ^a   Mayer, Karin ^a   Guth, Brian ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Contractility; Dog; Heart rate; Inotropy; Method; Telemetry

Indexed keywords

INOTROPIC AGENT; ITRACONAZOLE; PIMOBENDAN; UNCLASSIFIED DRUG; VETMEDIN;

ANIMAL EXPERIMENT; AORTA PRESSURE; ARTICLE; AUTOMATION; BODY TEMPERATURE; COMPUTER PROGRAM; DRUG MECHANISM; ELECTROCARDIOGRAM; FEMALE; HAPLORHINI; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART RATE VARIABILITY; MALE; MINIPIG; NONHUMAN; PRIMATE; TELEMETRY;

ANIMALS; ANIMALS, LABORATORY; BLOOD PRESSURE; CARDIOTONIC AGENTS; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HEART RATE; MACACA FASCICULARIS; MALE; MODELS, ANIMAL; MYOCARDIAL CONTRACTION; REPRODUCIBILITY OF RESULTS; SWINE; SWINE, MINIATURE; TELEMETRY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

ANIMALIA; CANIS FAMILIARIS; MACACA FASCICULARIS; PRIMATES;

EID: 84865634577     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.04.005     Document Type: Article

References (33)

1. Baumann G., Ningel K., Permanetter B. Clinical efficacy of Vetmedin (UD-CG 155 BS) in patients with chronic congestive heart failure. Journal of Cardiovascular Pharmacology 1989, 14(Suppl. 2):23-30.
2. Blinks J.R., Koch-Weser J. Analysis of the effects of changes in rate and rhythm upon myocardial contractility. Journal of Pharmacology and Experimental Therapeutics 1961, 134:373-389.
3. Braunwald E. Control of myocardial oxygen consumption. Physiologic and clinical considerations. The American Journal of Cardiology 1971, 27(4):416-432.
4. Brown J.M. Anesthesia and the contractile force of the heart. Anesthesia and Analgesia 1960, 39:487.
5. Buckley N.M., Penefsky Z.J., Litwak R.S. Comparative force-frequency relationships in human and other mammalian ventricular myocardium. Pflugers Archive 1972, 332:259-270.
6. Cools F., Janssens S., Vanlommel A., Teisman A., Towart R., Gallacher D. ECG arrhythmias in non-implanted vs. telemetry-implanted dogs: Need for screening before and sufficient recovery time after implantation. Journal of Pharmacological and Toxicological Methods 2011, 64(1):60-67.
7. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: Physiological and pathophysiological relevance. European Journal of Pharmacology 2004, 500:73-86.
8. Friedrichs G.S., Patmore L., Bass A. Non-clinical evaluation of ventricular repolarization (ICH S7B): Results of an interim survey of international pharmaceutical companies. Journal of Pharmacological and Toxicological Methods 2005, 52:6-11.
9. Gabel L.P., Bihler I., Dresel P.E. Contractility, metabolism and pharmacological reactions of isolated gas-perfused cat hearts. Circulation Research 1966, 19(5):891-902.
10. Gillebert T.C., Leite-Moreira A.F., De Hert S.G. Relaxation-systolic pressure relation: A load-independent assessment of left ventricular contractility. Circulation 1997, 95(3):745-752.
11. Guth B.D., Germeyer S., Kolb W., Markert M. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. Journal of Pharmacological and Toxicological Methods 2004, 49(3):159-169.
12. Hamlin R., Del Rio C. dP/dtmax- a Measure of "Barinometry". Journal of Pharmacological and Toxicological Methods 2012, 66:5-7.
13. Klumpp A., Trautmann T., Markert M., Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological and Toxicological Methods 2006, 54:141-149.
14. Li Z., Laugwitz K.-L., Pinkernell K., Pragst I., Baumgartner C., Hoffmann E., et al. Effects of two Gβγ-binding proteins - N-terminally truncated phosducin and β-adrenergic receptor kinase C terminus (βARKct) - In heart failure. Gene Therapy 2003, 10(16):1354-1361.
15. Markert M., Klumpp A., Trautmann T., Guth B. A novel propellant-free inhalation drug delivery system for cardiovascular drug safety evaluation in conscious dogs. Journal of Pharmacological and Toxicological Methods 2004, 50(2):109-119.
16. Markert M., Klumpp A., Trautmann T., Mayer K., Stubhan M., Guth B. The value added by measuring myocardial contractility "in vivo" in safety pharmacological profiling of drug candidates. Journal of Pharmacological and Toxicological Methods 2007, 56:203-211.
17. Markert M., Shen R., Trautmann T., Guth B. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development. Journal of Pharmacological and Toxicological Methods 2011, 64(1):25-41.
18. McCullagh P., Nelder J.A. Generalized linear models 1989, Chapman and Hall, London. Second Edition.
19. Meyners M., Markert M. Correcting the QT interval for changes in HR in pre-clinical drug development. Methods of Information in Medicine 2004, 43:445-450.
20. Miura T., Miyazaki S., Guth B.D., Indolfi C., Ross J. Heart rate and force-frequency effects on diastolic function of the left ventricle in exercising dogs. Circulation 1994, 89:2361-2368.
21. Nguyen V.T., Wu Y., Guillory A.N., McConnell B.K., Fujise K., Huang M.-H. Delta-opioid augments cardiac contraction through β-adrenergic and CGRP-receptor co-signaling. Peptides 2012, 33(1):77-82.
22. Pugsley M.K., Curtis M.J. Safety pharmacology in focus: New methods developed in the light of the ICH S7B guidance document. Journal of Pharmacological and Toxicological Methods 2006, 54(2):94-98.
23. Sagawa K. The ventricular pressure-volume diagram revisited. Circulation Research 1978, 43(5):677-687.
24. Sarazan R.D., Mittelstadt S., Guth B., Koerner J., Zhang J., Pettit S. Cardiovascular function in nonclinical drug safety assessment: Current issues and opportunities. International Journal of Toxicology 2011, 30(3):272-286.
25. Schildberg F.W., Fleckenstein A., Klek J. Die Bedeutung der extracellulären Calciumkonzentration für die Spaltung von energiereichem Phosphat in ruhendem und tätigem Myokardgewebe. Pflügers Archiv für die Gesamte Physiologie des Menschen und der Tiere 1965, 283(2):137-150.
26. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. The New England Journal of Medicine 1998, 339(13):900-905.
27. Suga H., Sagawa K. Instantaneous pressure volume relationships and their ratio in the excised, supported canine left ventricle. Circulation Research 1974, 35(1):117-126.
28. Suga H., Sagawa K., Kostiuk D.P. Controls of ventricular contractility assessed by pressure volume ratio, E(max). Cardiovascular Research 1976, 10(5):582-592.
29. Suga H., Sagawa K., Shoukas A.A. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circulation Research 1973, 32:314-322.
30. Templeton A., Byrne N., Calder C., Lambert S., Brown A., Shaw F., et al. Left ventricular pressure measurement in conscious dogs. Journal of Pharmacological and Toxicological Methods 2007, 56(2):67.
31. Van Citters R.L., Franklin D.L., Rushmer R.F. Left ventricular dynamics in dogs during anesthesia with alpha-chloralose and sodium pentobarbital. The American Journal of Cardiology 1964, 13:349-354.
32. Vatner S.F., Braunwald E. Cardiovascular control mechanisms in the conscious state. The New England Journal of Medicine 1975, 293(19):970-976.
33. Weber H., Berge E., Finsch J., Heidt P., Kaup F.-J., Perretta G., et al. Health monitoring of non-human primate colonies. Recommendations of the Federation of European Laboratory Animal Science Associations (FELASA) Working group on non-human primate health accepted by the FELASA board of management, 21 November 1998. Laboratory Animals 1999, 33:3-18.